1336963-95-1Relevant articles and documents
Fused pyridone compounds as kinase inhibitors
-
, (2021/09/01)
The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.
Quinazoline compound and application thereof in medicine (by machine translation)
-
, (2020/08/22)
The invention relates to a quinazoline compound (shown in the formula I) and a medicinal salt thereof, which can be used for treating cancer. The invention also relates to a preparation method and a pharmaceutical composition containing the compounds. (by machine translation)
2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF
-
, (2017/06/12)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, G1, G2, L1, L2, m1, m2, n, X and E are as defined herein, and wherein at least one of R3a, R3b, R4a or R4b is not H. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.